|
V.TLT
|
More likely, however, it's associated with management's assumptions. ...
|
|
V.TLT
|
Steven, RE your statement that "getting BTD solves everything...
|
|
V.TLT
|
...except we know the goal of finishing enrollment of 100 won't be...
|
|
V.TLT
|
Alamir, But then they seriously undertreated the first twelve patients...
|
|
V.TLT
|
Just a reminder that Theralase is only sponsoring the clinical trial, not...
|
|
V.TLT
|
The previous pp remains open with only the first tranche having been obtained...
|
|
V.TLT
|
You're not putting any money in the company coffers buying on the open...
|
|
V.TLT
|
The other day I looked back over the PP history all the way to 2015, and...
|
|
V.TLT
|
Recall that they entered into Phase II with around $10 million CDN which was...
|
|
V.TLT
|
As noted previously, the FDA has been stung in recent years when granting BTD...
|
|
V.TLT
|
Lesalpes29, Maybe you could take it to PM....
|
|
V.TLT
|
Indeed, Gooseybear, Thanks, God.
|
|
T.AOI
|
EGF, AOI does not control the number of lifts nor the timing which result in...
|
|
V.TLT
|
Pandora, The regulators didn't change anything here. Theralase...
|
|
V.TLT
|
Skys1, Never mind, I found Eoganaht's message from yesterday with the...
|
|
V.TLT
|
Skys1, How does one access the Conference Call? I tried getting an answer...
|
|
V.TLT
|
If you didn't presubmit your questions, don't expect answers.
|
|
V.TLT
|
Harvard Business Review, in studies dating as far back as the late 1950s, has...
|
|
V.TLT
|
Follow this at Provectus.Substack.com and on InvestorVillage.com One...
|
|
V.TLT
|
Try reading the Forward Looking Statement assicuated with each press release,
|